Valacyclovir Dosing Guidelines for Herpes Zoster

Immunocompetent Adults

• Prescribe valacyclovir 1000 mg orally three times daily for 7 days, initiating therapy within 72 hours of rash onset to maximize pain resolution and reduce post‑herpetic neuralgia. 1
• The CDC recommends the same 1000 mg every 8 hours regimen as the standard for herpes zoster in immunocompetent patients. 1
• Therapy is most effective when started within 48–72 hours of symptom onset; later initiation may still provide benefit. 2

Immunocompromised Adults

• The CDC advises against oral valacyclovir doses of 8 g per day in immunocompromised patients because of the risk of thrombotic thrombocytopenic purpura/hemolytic‑uremic syndrome. 2
• For severe disease with complications (e.g., disseminated infection, pneumonitis, hepatitis, or CNS involvement), use intravenous acyclovir 5–10 mg/kg every 8 hours for 5–7 days instead of oral valacyclovir. 2

Pediatric Patients

Adolescents (≥12 years)

• When able to tolerate adult dosing, the CDC recommends valacyclovir 1 g three times daily for 7 days. 1

Children <12 years (unable to take valacyclovir)

• Acyclovir 20 mg/kg orally four times daily (maximum 800 mg per dose) is the preferred alternative. 1

Severe VZV disease or acute retinal necrosis in children eligible for adult dosing

• The CDC recommends intravenous acyclovir 10 mg/kg three times daily for 10–14 days, followed by oral valacyclovir 1 g three times daily for 4–6 weeks. 1

Renal Impairment

• Valacyclovir dosing must be adjusted according to creatinine clearance in patients with reduced renal function. 1
• The National Kidney Foundation emphasizes careful dose reduction based on measured creatinine clearance to avoid toxicity. 1

General Management Pitfalls

• Do not postpone antiviral therapy awaiting laboratory confirmation; initiate treatment based on clinical presentation within 72 hours of rash onset. 2
• Topical antivirals alone are not effective for VZV conjunctivitis and should not be used as monotherapy. 3
• Maintain adequate hydration throughout the course of therapy to lessen the risk of renal toxicity. 4